Breaking chains of gluten-immunogenic peptides

Solutions for gluten-related disorders

AMYRA

Biotech AG

AMYRA Biotech AG

AMYRA Biotech AG is a private Swiss joint stock company, founded in 2013.

The multidisciplinary team brings together complementary expertise in drug development, biotechnology, immunology, medicine and business.

AMYRA collaborates intensively with universities, research institutes, industry partners and healthcare professionals.

AMYRA's mission is to deliver effective and safe treatments for gluten related disorders.​

Dr. Werner Tschollar, CEO & founder

AMYRA's mission is to deliver effective and safe treatments for gluten related disorders.​

Dr. Werner Tschollar, CEO & founder

A unique approach

AMYRA Products

Foundation

Scientific research has shown that partially digested gluten fragments, known as gluten immunogenic peptides (GIPs) trigger an autoimmune response in genetically predisposed people, namely celiac disease.

GIPs also play a role in the immune pathology of  non-celiac gluten sensitivity, a clinical syndrome distinct from celiac disease. 

AMYRA develops GIP-degrading enzymes as oral treatments for both celiac disease and non-celiac gluten sensitivity. 

development

Latest Updates

Q2 2020

AMY01 is currently undergoing a GRAS (generally recognized as safe) notice application in the US and will soon undergo the “novel food” application in Europe.

AMYRA intends to partner the dietary supplement AMY01 with a global consumer health company for marketing, sales and distribution. This will soon give people affected by non-celiac gluten sensitivity access to our product .